SSA
XFOR icon

Schonfeld Strategic Advisors’s X4 Pharmaceuticals XFOR Stock Holding History

Schonfeld Strategic Advisors’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80.6K Buy
+19,514
New +$73.1K ﹤0.01% 1916
2025
Q3 		– Sell
-11,261
Closed -$21.4K – 2632
2025
Q2 		$21.4K Buy
11,261
+80
+0.7% +$327 ﹤0.01% 1931
2025
Q1 		$79.3K Sell
11,181
-35,247
-76% -$485K ﹤0.01% 2040
2024
Q4 		$1.02M Sell
46,428
-17,599
-27% -$281K 0.01% 1102
2024
Q3 		$1.29M Buy
64,027
+21,704
+51% +$453K 0.01% 1072
2024
Q2 		$736K Buy
42,323
+11,823
+39% +$387K ﹤0.01% 1336
2024
Q1 		$1.27M Buy
30,500
+12,190
+67% +$339K 0.01% 1139
2023
Q4 		$461K Sell
18,310
-1,225
-6% -$29.8K ﹤0.01% 1313
2023
Q3 		$639K Sell
19,535
-13,255
-40% -$578K 0.01% 1146
2023
Q2 		$1.91M Sell
32,790
-1,777
-5% -$91.3K 0.02% 766
2023
Q1 		$902K Buy
34,567
+4,724
+16% +$139K 0.01% 995
2022
Q4 		$889K Buy
+29,843
New +$1.41M 0.01% 1210

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Schonfeld Strategic Advisors's XFOR Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in X4 Pharmaceuticals (XFOR) in Q1 2026: 19,514 shares worth $80.6K. The stake represents ﹤0.01% of the portfolio and ranks #1916 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in XFOR as recently as Q2 2025.

Schonfeld Strategic Advisors first reported a position in XFOR in Q4 2022 and has held it in 12 quarters since. The position peaked at $1.91M in Q2 2023. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

  • Schonfeld Strategic Advisors held 19,514 shares of X4 Pharmaceuticals worth $80.6K as of Q1 2026.
  • X4 Pharmaceuticals was a new Schonfeld Strategic Advisors position in Q1 2026.
  • X4 Pharmaceuticals made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1916 holding.
  • Schonfeld Strategic Advisors first reported a position in X4 Pharmaceuticals in Q4 2022 and has held it in 12 quarters since.
  • Schonfeld Strategic Advisors's X4 Pharmaceuticals position peaked at $1.91M in Q2 2023.
  • 84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.